PATIENT CARE
CUTTING EDGE THERAPIES
EXPERT PHYSICIANS

New Standard of Care for people with relapsed or refractory large B-cell lymphoma.





Join the Fight

AND GET BETTER RESULTS WITH THE NEW CAR T-CELL THERAPY YESCARTA®

54 WELLINGTON ROAD
BIRMINGHAM, B15 2TT
555-543-5432
WWW.MIDLANDSCENTER.COM

MIDLANDS CENTER
FOR LYMPHOMA & CELLULAR THERAPY







MIDLANDS CENTER
FOR LYMPHOMA & CELLULAR THERAPY


150,000

NEW LBCL CASES WORLDWIDE EACH YEAR



CAR T-CELL THERAPY: A personalized approach of treating lymphoma





NO WORSENING OF THE CANCER AT 2 YEARS IN 40% OF PATIENTS

65%

ACHIEVED COMPLETE REMISSION


THE RESULTS

THE ZUMA-7 STUDY GIVES NEW HOPE FOR LYMPHOMA PATIENTS

Approximately 40% of patients with large B-cell lymphoma (LBCL) are not cured by first-line chemoimmunotherapy. Historically, outcomes for these patients have been poor.

The ZUMA-7 clinical trial evaluated a new second-line CAR T-cell therapy in 180 patients with relapsed (returned) or refractory (treatment-resistant) LBCL. The study assessed survival without disease-related events, treatment response, overall survival, and safety. Results were compared with those of 179 patients who received the previous standard

Patients treated with Yescarta ® were more likely to respond to treatment, with an overall response rate of 83%, compared with 50% in the standard treatment group. 65% of patients treated with Yescarta achieved a complete remission, compared with 32% of patients receiving standard treatment. Patients treated with Yescarta were also more likely to remain free from disease-related events (41% vs 16%).



WHAT IS YESCARTA ®?

Yescarta is the brand name for axicabtagene ciloleucel (axi-cel). It is a type of cancer immunotherapy known as CAR T-cell therapy.

HOW DOES IT WORK?

Treatment begins with the collection of the patient's own T cells, a type of white blood cell that helps fight infections. These T cells are then genetically modified in a laboratory to have chimeric antigen receptors (CARs) which turn them into CAR T cells.

Once infused, the CAR T cells travel throughout the body, where they multiply and recognize and destroy cancer cells by targeting specific markers on their surface called CD19 antigens.

Is everybody eligible for this therapy?

Not every patient is a candidate for CAR T-cell therapy. Our healthcare team will assess your overall health, medical history, and individual circumstances to determine whether Yescarta is an appropriate treatment option for you. Among eligible patients, Yescarta demonstrated consistent results across different age groups, LBCL subtypes, and risk categories.

MORE THAN 25,000 PATIENTS TREATED WITH YESCARTA

Ask your doctor if YESCARTA® is an option for you.

WHAT ARE POSSIBLE SIDE EFFECTS?

Like most cancer treatments, Yescarta may cause side effects. In the ZUMA-7 study, approximately 9 out of 10 patients experienced a condition known as cytokine release syndrome (CRS), while 6 out of 10 patients experienced neurological events.

Although these side effects were relatively common, severe cases were less frequent, occurring in 6% of patients with CRS and 21% of patients with neurological side effects. All cases of CRS and most neurological side effects resolved within a few days.

CYTOKINE RELEASE SYNDROME (CRS)


CRS is caused by activation of the immune system and the release of inflammatory messenger proteins called cytokines. Elevated cytokine levels may lead to symptoms such as fever, low blood pressure, fatigue, and muscle aches.
In most patients, these symptoms began around 3 days after infusion and typically lasted for approximately 7 days.

NEUROLOGICAL EVENTS

Neurological side effects affect the nervous system and may include confusion, difficulty speaking, tingling sensations, and tremors.

These symptoms most commonly occurred around 7 days after infusion

ALL CRS AND MOST NEUROLOGIC EVENTS RESOLVE WITHIN FEW DAYS



TREATMENT JOURNEY

Treatment with Yescarta can take several weeks and is typically divided into five main steps:

1. CAR T CONSULTATION: During one or more appointments, your healthcare team will determine whether you are an eligible treatment candidate. This assessment may include blood tests and other examinations. You and your caregivers will also receive detailed information about the treatment process.

2. LEUKAPHERESIS: During this first full-day hospital visit, your blood is passed through a machine that collects the T cells needed to manufacture your Yescarta treatment.


3. MANUFACTURING YOUR CAR T-CELLS: Your collected T cells are sent to a specialized Yescarta manufacturing facility, where they are genetically modified to create CAR T cells. This process typically takes around two weeks. Meanwhile, your healthcare team may decide to provide temporary treatment, known as bridging therapy, to

4. LOW DOSE CHEMOTHERAPY: The purpose of this chemotherapy is not to treat your cancer, but to prepare your immune system for the Yescarta infusion. This step requires three consecutive visits to the treatment center. A two-day rest period follows before treatment.

5. YESCARTA INFUSION AND MONITORING: Approximately one hour before the infusion, you will receive pre-medication to help reduce the risk of infusion-related reactions.

The Yescarta infusion itself takes about 30 minutes and may be administered either as an inpatient or outpatient procedure.

Following infusion, you will be monitored closely for at least one week for signs of side effects. Ongoing follow-up and monitoring will continue for several weeks after treatment.



SIDE EFFECT MANAGEMENT

At the Midlands Centre, patient safety is our highest priority. For this reason, all patients are monitored daily for the first 7 days following their Yescarta® infusion for signs of cytokine release syndrome, neurological side effects, and other adverse events. In some cases, patients may be admitted to hospital during this period as a precaution.

Monitoring continues beyond the initial 7 days, and both patients and their caregivers receive guidance on how to recognize the signs and symptoms of CRS and neurological side effects. We also recommend that patients remain within close proximity of the Midlands Centre for the first 4 weeks after infusion and contact their healthcare team immediately if any symptoms occur, so that appropriate medical care can be provided as soon as possible.

WHO SHOULD I CONTACT IN CASE OF SIDE EFFECTS?

If you or the person you take care of develops fever, confusion, difficulty speaking, shortness of breath, severe fatigue, or any other concerning symptoms, contact your treatment team immediately.

MIDLANDS CENTER
FOR LYMPHOMA & CELLULAR THERAPY

24/7 Support Line: +44 (0)121 555 7420

Daytime Contact: +44 (0)121 555 7410